生命科学资讯

Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans

'When the markets opened, we were ready': Why biotech IPOs are back for 2026

PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna

Illumina, Inc. $ILMN Stock Holdings Lowered by Rhumbline Advisers - MarketBeat

10x Genomics, Inc. SEC 10-K Report - TradingView

FDA Ovarian Cancer Nod Puts Focus On Agilent Valuation And Momentum - simplywall.st

Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Agilent Receives FDA Approval for Companion Diagnostic in Ovarian Cancer - Femtech Insider

Is Waters a Better Buy Than Thermo Fisher Scientific? - Trefis

10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpass - GuruFocus

10x Genomics Q4 Earnings Call Highlights - MarketBeat

10x Genomics Q4 Earnings Call Highlights - MarketBeat

Ultragenyx to lay off about 130 employees after rough 2025

Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Nasdaq

Thermo Fisher Scientific Inc. (TMO): Our Calculation of Intrinsic Value - The Acquirer's Multiple

Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor

Thermo Fisher Issues $3.8 Billion Notes for Acquisition - TipRanks

10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025 - Yahoo Finance

10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat